Alpha Cognition (ACOG) said the USPTO published its patent application covering proprietary manufacturing technology for benzgalantamine, the active ingredient in ZUNVEYL. The application aims to improve efficiency, quality, and scalability. CEO Michael McFadden said it supports the company's IP strategy.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
